The FDA accepted the filings for review and set a target decision date of February 28, 2027. The applications rely on results ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that ...
The U.S. Food and Drug Administration (FDA) accepted on Tuesday Sarepta Therapeutics Inc.’s SRPT supplemental New Drug ...
Sarepta Therapeutics stock (NASDAQ: SRPT) experienced a significant turnaround on Wednesday, with shares rising 33% in after-hours trading following the announcement of an extensive restructuring plan ...
Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.
Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options begin trading today, for the September 19th expiration. One of the key data points that goes into the price an option buyer is ...
Zacks Investment Research on MSN
SRPT or PRTA: Which is the better value stock right now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Sarepta Therapeutics (SRPT) and Prothena (PRTA). But which of these two stocks is more attractive to value ...
Sarepta Therapeutics faces a challenging outlook, with 2025 marked by safety setbacks, missed endpoints, and a sharp price decline. See why SRPT stock is a hold.
Sarepta Therapeutics (NASDAQ: SRPT) suffered a devastating blow on Monday, June 16 when its stock plummeted 42% following news of a second patient death linked to its Duchenne muscular dystrophy gene ...
Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options begin trading this week, for the December 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results